Aviva appoints new CEO who admits there is 'substantial work to do'

Life assurer Aviva's brand new Chief Executive Officer (CEO), Mark Wilson, has admitted to investors that there is 'substantial work to do', but promised he will listen to stakeholders.

Life assurer Aviva's brand new Chief Executive Officer (CEO), Mark Wilson, has admitted to investors that there is 'substantial work to do', but promised he will listen to stakeholders.

Wilson, who is to join the board on December 1st and become CEO exactly one month later, was previously the CEO and President of AIA Group, a big player in the world of insurance companies between 2006 and 2010.

Wilson said: "It is acknowledged that over recent years the company has not performed to its potential. The Chairman, John McFarlane, and the board have articulated the first stage of the strategy that addresses the immediate issues and I look forward to continue working closely with the board on these priorities. The company will initially be judged on the execution of that strategy and I intend to pursue the execution with rigour and focus.

"My first task will be to listen to Aviva's stakeholders, including customers, shareholders, staff and regulators and ascertain the key concerns and opportunities that face the business. There is substantial work to do. I am looking forward to taking up this appointment and excited about the future prospects for Aviva."

The director has over twenty-five years' experience in the insurance industry across life and general insurance, as well as asset management in both mature and emerging markets. Since leaving AIA, he has been involved in private equity with Blackstone and other private equity firms.

The company also announced that John McFarlane, the Chairman of Aviva, who has also been acting in an executive capacity pending the appointment of a CEO, will become non-executive Chairman on January 1st next year.

McFarlane said of Wilson's appointment: "I am delighted we have secured Mark for Aviva. His leadership credentials are incredibly strong. He has an outstanding track record of leading a major insurer, of transforming its performance and culture, of implementing a growth agenda and of producing significant shareholder value, all of which are essential for Aviva's success going forward."

CM

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022